HTG Molecular Diagnostics Announces Immuno-Oncology Research Collaboration Agreement with Bristol-Myers Squibb
May 12 2016 - 4:01PM
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of
instruments and reagents for molecular profiling applications,
today announced a research collaboration agreement with
Bristol-Myers Squibb (NYSE:BMY) to evaluate the potential for
immuno-oncology molecular profiling in multiple tumor types. The
collaboration between HTG and Bristol-Myers Squibb will utilize the
next generation sequencing (NGS)-based HTG EdgeSeq system as a tool
for use in support of Bristol-Myers Squibb’s translational research
activities.
"We believe this collaboration will provide many benefits to
Bristol-Myers Squibb’s immuno-oncology development programs and
further add to HTG’s industry leadership in the development of
NGS-based molecular diagnostic assays toward the goal of precision
medicine. This collaboration is the result of a long-standing
Bristol-Myers Squibb/HTG relationship and we are excited to
continue as a partner with Bristol-Myers Squibb’s translational
research team,” said John Lubniewski, HTG’s Chief Business
Officer.
Under the terms of the agreement, HTG will provide Bristol-Myers
Squibb access to its NGS-based HTG EdgeSeq system and the
companies will collaborate to develop tools for use for molecular
profiling research for immuno-oncology.
“Immuno-oncology is a very important business segment for us and
this agreement and the expansion of our relationship with BMS is a
validation of our HTG EdgeSeq technology and value proposition,”
stated TJ Johnson, President and CEO of HTG Molecular Diagnostics.
“We firmly believe in the potential of immuno therapies in treating
cancer patients and we are honored to be chosen as a profiling
partner for Bristol-Myers Squibb, a recognized leader in this
space.”
About HTG:
Headquartered in Tucson, Arizona, HTG’s mission is to empower
precision medicine at the local level. In 2013 the company
commercialized its HTG Edge instrument platform and a portfolio of
RNA assays that leverage HTG's proprietary nuclease protection
chemistry. HTG’s product offerings have since expanded to include
its HTG EdgeSeq product line, which automates sample and
targeted library preparation for next-generation sequencing.
Additional information is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with the expected benefits
of our agreement with BMS, the role that immuno-oncology molecular
profiling will have in clinical settings, including precision
medicine, the potential of immunotherapy treatments, and our
business and the capabilities of our technology. Words such as
"believes," "anticipates," "plans," "expects," "intends," "will,"
"goal," "potential" and similar expressions are intended to
identify forward-looking statements, though not all forward-looking
statements necessarily contain these identifying words. These
forward-looking statements are based upon management's current
expectations, are subject to known and unknown risks, and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties,
including, without limitation, risks associated with the process of
developing and commercializing immuno-oncology applications and
biomarker panels. These and other factors are described in greater
detail in our filings with the Securities and Exchange Commission,
including without limitation our Quarterly Report on Form 10-Q for
the quarter ended March 31, 2016. All forward-looking statements
contained in this press release speak only as of the date on which
they were made, and we undertake no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Contact:
Westwicke Partners
Jamar Ismail
Phone: 415-513-1282
Email: jamar.ismail@westwicke.com
TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x130
Email: tjjohnson@htgmolecular.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024